Surain B Roberts,Woo Jin Choi,Lawrence Worobetz,Catherine Vincent,Jennifer A Flemming,Angela Cheung,Karim Qumosani,Mark Swain,Dusanka Grbic,Hin Hin Ko,Kevork M Peltekian,Lusine Abrahamyan,Monika Saini,Kattleya Tirona,Bishoi Aziz,Ellina Lytvyak,Pietro Invernizzi,Cyriel Y Ponsioen,Tony Bruns,Nora Cazzagon,Keith Lindor,George N Dalekos,Nikolaos K Gatselis,Xavier Verhelst,Annarosa Floreani,Christophe Corpechot,Marlyn J Mayo,Cynthia Levy,Maria-Carlota Londoño,Pier M Battezzati,Albert Pares,Frederik Nevens,Adriaan van der Meer,Kris V Kowdley,Palak J Trivedi,Ana Lleo,Douglas Thorburn,Marco Carbone,Nazia Selzner,Aliya F Gulamhusein,Harry LA Janssen,Aldo J Montano-Loza,Andrew L Mason,Gideon M Hirschfield,Bettina E Hansen,Canadian Network for Autoimmune Liver disease (CaNAL)

Abstract:Background & aims: Biochemical response to ursodeoxycholic acid (UDCA) therapy is associated with good prognosis in people living with primary biliary cholangitis (PBC). Biochemical response is typically assessed early in disease and it is not known what proportion of patients lose previously attained biochemical response, nor whether this impacts long-term liver transplant (LT)-free survival. Methods: We identified all UDCA-treated patients with PBC from the Canadian Network for Autoimmune Liver disease with biochemical measurements at 1 year, and evaluated their liver biochemistry over time. Inadequate biochemical response was defined as serum alkaline phosphatase ≥1.67x the upper limit of normal or abnormal serum total bilirubin at 1 year of UDCA therapy and all time points thereafter. Multistate Markov models were used to estimate transition rates between biochemical response states and from each state to LT or death. Results were validated in an external cohort (GLOBAL PBC registry). Results: A total of 823 patients from eight centers were included. Mean age at diagnosis was 53 years, 91% were female, 33% had inadequate biochemical response to UDCA at 1 year (n = 269). Patients who retained initial adequate response had lower rates of LT or death compared to patients who subsequently lost response (relative rate 0.102, 95% CI 0.047-0.223). Patients who regained adequate response had lower rates than patients who did not (0.016, 95% CI 0.001-0.568), and patients who lost response once more (0.010, 95% CI 0.001-0.340). Patients who regained adequate response for a third time also had lower rates than patients who did not (0.151, 95% CI 0.040-0.566). Analyses in the GLOBAL PBC registry (n = 2,237) validated these results. Conclusion: Loss of biochemical response at any time is associated with heightened risks of LT or death in people living with PBC. Achievement of biochemical response is an important goal throughout follow-up, regardless of biochemical response profile early in therapy. Impact and implications: Early biochemical response to ursodeoxycholic acid is associated with good prognosis in patients with primary biliary cholangitis (PBC). Our work demonstrates that patients with PBC transition between biochemical response states over time, and that these transitions correspond with changes in risk of liver transplantation or death. Clinicians should re-evaluate risk and optimize treatment decisions for patients with PBC throughout follow-up, regardless of early biochemical response to therapy.

Gut microbiome pattern impacts treatment response in primary biliary cholangitis

Evidence for the Association Between IgG‐antimitochondrial Antibody and Biochemical Response to Ursodeoxycholic Acid Treatment in Primary Biliary Cholangitis

IDDF2024-ABS-0186 Analysis of the Correlation Between Gut Microbiota and Disease Severity in Patients with Primary Biliary Cholangitis

Distinct signatures of gut microbiota and metabolites in primary biliary cholangitis with poor biochemical response after ursodeoxycholic acid treatment

Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis.

Insights from the Gut Microbiota–Bile Acid–Immunity Network

Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

The fecal microbiota of patients with primary biliary cholangitis (PBC) causes PBC-like liver lesions in mice and exacerbates liver damage in a mouse model of PBC

Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis A meta-analysis

Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis

High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study

Combination Therapy of Ursodeoxycholic Acid and Glucocorticoid and (or) Immunosuppressant in Patients with Primary Biliary Cholangitis

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

Research on gut microbiota characteristics of PBC patients at different ALBI grades based on machine learning

Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion